|
US8003662B2
(en)
|
2006-01-30 |
2011-08-23 |
Array Biopharma, Inc. |
Heterobicyclic thiophene compounds and methods of use
|
|
TWI398252B
(zh)
|
2006-05-26 |
2013-06-11 |
諾華公司 |
吡咯并嘧啶化合物及其用途
|
|
WO2009002933A1
(en)
*
|
2007-06-22 |
2008-12-31 |
Hydra Biosciences, Inc. |
Methods and compositions for treating disorders
|
|
GB0722055D0
(en)
*
|
2007-11-09 |
2007-12-19 |
Argenta Discovery Ltd |
Compounds
|
|
EP2231600B1
(en)
*
|
2007-11-16 |
2015-07-29 |
Rigel Pharmaceuticals, Inc. |
Carboxamide, sulfonamide and amine compounds for metabolic disorders
|
|
BRPI0821115A8
(pt)
*
|
2007-12-18 |
2017-12-26 |
Actelion Pharmaceuticals Ltd |
Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
|
|
AU2008343932B2
(en)
|
2007-12-19 |
2013-08-15 |
Amgen Inc. |
Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
|
|
KR101247840B1
(ko)
|
2008-02-22 |
2013-03-26 |
에프. 호프만-라 로슈 아게 |
아밀로이드 베타 조절제
|
|
CA2718727A1
(en)
*
|
2008-03-25 |
2009-10-01 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
|
ATE531372T1
(de)
|
2008-04-07 |
2011-11-15 |
Amgen Inc |
Gem-disubstituierte und spirocyclische aminopyridine/pyrimidine als zellcyclus- inhibitoren
|
|
WO2009140517A1
(en)
|
2008-05-14 |
2009-11-19 |
Hydra Biosciences, Inc. |
Compounds and compositions for treating chemical warfare agent-induced injuries
|
|
GB0812969D0
(en)
|
2008-07-15 |
2008-08-20 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
|
AU2009284098B2
(en)
|
2008-08-22 |
2012-03-29 |
Astex Therapeutics Ltd. |
Pyrrolopyrimidine compounds as CDK inhibitors
|
|
WO2011036889A1
(ja)
*
|
2009-09-25 |
2011-03-31 |
武田薬品工業株式会社 |
複素環化合物
|
|
WO2011036885A1
(ja)
*
|
2009-09-25 |
2011-03-31 |
武田薬品工業株式会社 |
複素環化合物
|
|
US8486967B2
(en)
*
|
2010-02-17 |
2013-07-16 |
Hoffmann-La Roche Inc. |
Heteroaryl substituted piperidines
|
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
|
EP2552893B1
(en)
|
2010-03-31 |
2014-10-29 |
Actelion Pharmaceuticals Ltd. |
Antibacterial isoquinolin-3-ylurea derivatives
|
|
GB201007286D0
(en)
|
2010-04-30 |
2010-06-16 |
Astex Therapeutics Ltd |
New compounds
|
|
WO2012005805A1
(en)
*
|
2010-05-07 |
2012-01-12 |
Glaxosmithkline Llc |
Azaindazoles
|
|
EP2571361A4
(en)
|
2010-05-19 |
2013-11-13 |
Univ North Carolina |
PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
|
|
JP6063870B2
(ja)
|
2010-11-08 |
2017-01-18 |
ライセラ・コーポレイション |
ＲＯＲγ活性の阻害用のＮ−スルホニル化テトラヒドロキノリンおよび関連二環化合物および病気の治療
|
|
GB201020179D0
(en)
|
2010-11-29 |
2011-01-12 |
Astex Therapeutics Ltd |
New compounds
|
|
CA2817460A1
(en)
|
2010-12-17 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
|
|
WO2012088266A2
(en)
|
2010-12-22 |
2012-06-28 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
|
|
US9133187B2
(en)
|
2011-02-28 |
2015-09-15 |
Array Biopharma Inc. |
Serine/threonine kinase inhibitors
|
|
WO2012120055A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
EP2766349B1
(de)
|
2011-03-08 |
2016-06-01 |
Sanofi |
Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
WO2012120054A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
WO2012120056A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
EP2683704B1
(de)
|
2011-03-08 |
2014-12-17 |
Sanofi |
Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
|
KR101606250B1
(ko)
|
2011-03-23 |
2016-03-24 |
암젠 인크 |
Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제
|
|
AR088729A1
(es)
|
2011-03-29 |
2014-07-02 |
Actelion Pharmaceuticals Ltd |
Derivados de 3-ureidoisoquinolin-8-ilo y una composicion farmaceutica
|
|
ES2552989T3
(es)
*
|
2011-08-04 |
2015-12-03 |
Array Biopharma, Inc. |
Compuestos de quinazolina como inhibidores de la cinasa de serina / treonina
|
|
BR112014003981A2
(pt)
|
2011-08-23 |
2017-03-07 |
Endo Pharmaceuticals Inc |
compostos de pirimido-piridazinona e seu uso
|
|
EP2567959B1
(en)
|
2011-09-12 |
2014-04-16 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
BR112014007788A2
(pt)
|
2011-10-03 |
2017-04-18 |
Univ North Carolina Chapel Hill |
compostos de pirrolopirimidina para tratamento do câncer
|
|
GB201118675D0
(en)
|
2011-10-28 |
2011-12-14 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201118654D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201118652D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201118656D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
|
PE20150666A1
(es)
|
2012-03-01 |
2015-05-06 |
Array Biopharma Inc |
Inhibidores de serina/treonina cinasa
|
|
EA029892B1
(ru)
|
2012-04-25 |
2018-05-31 |
Такеда Фармасьютикал Компани Лимитед |
Азотсодержащее гетероциклическое соединение
|
|
RU2014149136A
(ru)
|
2012-05-08 |
2016-07-10 |
Мерк Шарп И Доум Корп. |
ТЕТРАГИДРОНАФТИРИДИНОВЫЕ И РОДСТВЕННЫЕ БИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ ДЛЯ ИНГИБИРОВАНИЯ RORγ АКТИВНОСТИ И ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ
|
|
EP2847198B1
(en)
|
2012-05-08 |
2016-12-14 |
Lycera Corporation |
Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of ror-gamma and the treatment of disease
|
|
JP2015517574A
(ja)
|
2012-05-22 |
2015-06-22 |
ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル |
がん治療のためのピリミジン化合物
|
|
GB201209613D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201209609D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
|
CA2876689C
(en)
|
2012-06-13 |
2022-04-26 |
Incyte Corporation |
Substituted tricyclic compounds as fgfr inhibitors
|
|
JP6205356B2
(ja)
|
2012-07-13 |
2017-09-27 |
武田薬品工業株式会社 |
複素環化合物
|
|
ES2668694T3
(es)
*
|
2012-07-27 |
2018-05-21 |
Biogen Ma Inc. |
Derivados de ácido 1-[7-(cis-4-metil-ciclohexiloxi)-8-trifluorometil-naftalen-2-ilmetil]-piperidin-4-carboxílico como moduladores de autotaxina (ATX) para tratar inflamaciones y trastornos autoinmunitarios
|
|
CA2881279C
(en)
*
|
2012-08-07 |
2020-07-07 |
Merck Patent Gmbh |
Pyridopyrimidine derivatives as protein kinase inhibitors
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
US9487526B2
(en)
|
2012-08-13 |
2016-11-08 |
Takeda Pharmaceutical Company Limited |
Quinoxaline derivatives as GPR6 modulators
|
|
CA2882750A1
(en)
*
|
2012-08-27 |
2014-03-06 |
Jim Blake |
Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases
|
|
GB201216017D0
(en)
|
2012-09-07 |
2012-10-24 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
|
GB201216018D0
(en)
|
2012-09-07 |
2012-10-24 |
Cancer Rec Tech Ltd |
Pharmacologically active compounds
|
|
WO2014047374A1
(en)
|
2012-09-21 |
2014-03-27 |
Bristol-Myers Squibb Company |
Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds
|
|
EP2897954B1
(en)
|
2012-09-21 |
2016-10-26 |
Bristol-Myers Squibb Company |
Fluoroalkyl-1,4-benzodiazepinone compounds
|
|
WO2014044846A1
(en)
|
2012-09-24 |
2014-03-27 |
Evotec (Uk) Ltd. |
3-(aryl- or heteroaryl-amino)-7-(3,5-dimethoxyphenyl)isoquinoline derivatives as fgfr inhibitors useful for the treatment of proliferative disorders or dysplasia
|
|
WO2014062774A1
(en)
|
2012-10-17 |
2014-04-24 |
The University Of North Carolina At Chapel Hill |
Pyrazolopyrimidine compounds for the treatment of cancer
|
|
WO2014060381A1
(de)
*
|
2012-10-18 |
2014-04-24 |
Bayer Cropscience Ag |
Heterocyclische verbindungen als schädlingsbekämpfungsmittel
|
|
WO2014085225A1
(en)
|
2012-11-27 |
2014-06-05 |
The University Of North Carolina At Chapel Hill |
Pyrimidine compounds for the treatment of cancer
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
US9353122B2
(en)
|
2013-02-15 |
2016-05-31 |
Kala Pharmaceuticals, Inc. |
Therapeutic compounds and uses thereof
|
|
US9688688B2
(en)
|
2013-02-20 |
2017-06-27 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
|
|
US9353123B2
(en)
|
2013-02-20 |
2016-05-31 |
Kala Pharmaceuticals, Inc. |
Therapeutic compounds and uses thereof
|
|
EP2975031A4
(en)
|
2013-03-14 |
2017-04-19 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
|
CN104098563A
(zh)
*
|
2013-04-02 |
2014-10-15 |
山东亨利医药科技有限责任公司 |
Jnk抑制剂化合物
|
|
PH12015502383B1
(en)
|
2013-04-19 |
2023-02-03 |
Incyte Holdings Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
GB201307577D0
(en)
|
2013-04-26 |
2013-06-12 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
EP3018126A4
(en)
|
2013-07-03 |
2016-12-07 |
Takeda Pharmaceuticals Co |
HETEROCYCLIC CONNECTION
|
|
JP6411342B2
(ja)
|
2013-07-03 |
2018-10-24 |
武田薬品工業株式会社 |
アミド化合物
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
JPWO2015012328A1
(ja)
|
2013-07-24 |
2017-03-02 |
武田薬品工業株式会社 |
複素環化合物
|
|
EP4772247A2
(en)
|
2013-08-14 |
2026-07-08 |
Novartis AG |
Combination therapy comprising ribociclib and fulvestrant for the treatment of cancer
|
|
US9890173B2
(en)
|
2013-11-01 |
2018-02-13 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
|
KR20160099084A
(ko)
|
2013-11-01 |
2016-08-19 |
칼라 파마슈티컬스, 인크. |
치료 화합물의 결정질 형태 및 그의 용도
|
|
EP3078660B1
(en)
*
|
2013-12-06 |
2022-07-13 |
MycHunter Therapeutics, Inc. |
Novel quinazoline derivative
|
|
WO2015095795A1
(en)
|
2013-12-20 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
|
|
WO2015095788A1
(en)
|
2013-12-20 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
|
|
JO3466B1
(ar)
|
2013-12-20 |
2020-07-05 |
Takeda Pharmaceuticals Co |
مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
|
|
WO2015095792A1
(en)
|
2013-12-20 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease
|
|
RU2016134751A
(ru)
|
2014-01-29 |
2018-03-02 |
Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Соединения
|
|
SG11201605342UA
(en)
|
2014-01-29 |
2016-08-30 |
Glaxosmithkline Ip Dev Ltd |
Compounds
|
|
JP6526034B2
(ja)
|
2014-02-14 |
2019-06-05 |
武田薬品工業株式会社 |
Ｇｐｒ６のピリドピラジンモジュレーター
|
|
AU2015222917A1
(en)
|
2014-02-27 |
2016-09-15 |
Lycera Corporation |
Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
|
|
GB201403536D0
(en)
|
2014-02-28 |
2014-04-16 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
|
JO3512B1
(ar)
|
2014-03-26 |
2020-07-05 |
Astex Therapeutics Ltd |
مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
|
|
BR112016022056B1
(pt)
|
2014-03-26 |
2023-04-11 |
Astex Therapeutics Limited |
Combinação, composição farmacêutica, uso de uma combinação ou uma composição farmacêutica, e, produto farmacêutico
|
|
US10736900B2
(en)
|
2014-03-26 |
2020-08-11 |
Astex Therapeutics Ltd |
Combinations of an FGFR inhibitor and an IGF1R inhibitor
|
|
US9649309B2
(en)
|
2014-04-11 |
2017-05-16 |
The University Of North Carolina At Chapel Hill |
Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
WO2015171558A2
(en)
|
2014-05-05 |
2015-11-12 |
Lycera Corporation |
BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
|
|
EP3140291A4
(en)
|
2014-05-05 |
2018-01-10 |
Lycera Corporation |
Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
|
|
US9758518B2
(en)
|
2015-03-04 |
2017-09-12 |
Pimera, Inc. |
Compositions, uses and methods for making them
|
|
BR112016026150B1
(pt)
|
2014-05-09 |
2019-11-05 |
Pimera, Inc. |
compostos carboxílicos e seu uso na preparação de medicamentos ou composições farmacêuticas para tratar câncer
|
|
WO2016015597A1
(en)
|
2014-07-26 |
2016-02-04 |
Sunshine Lake Pharma Co., Ltd. |
Compounds as cdk small-molecule inhibitors and uses thereof
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
CA2972014C
(en)
|
2014-12-24 |
2019-09-24 |
Gilead Sciences, Inc. |
Fused pyrimidine compounds for the treatment of hiv
|
|
SG11201705184PA
(en)
|
2014-12-24 |
2017-07-28 |
Gilead Sciences Inc |
Isoquinoline compounds for the treatment of hiv
|
|
TWI770552B
(zh)
|
2014-12-24 |
2022-07-11 |
美商基利科學股份有限公司 |
喹唑啉化合物
|
|
WO2016126570A1
(en)
*
|
2015-02-06 |
2016-08-11 |
Merck Sharp & Dohme Corp. |
Aminoquinazoline compounds as a2a antagonist
|
|
TWI719960B
(zh)
|
2015-02-10 |
2021-03-01 |
英商阿斯迪克治療公司 |
新穎組成物
|
|
CA2975997A1
(en)
|
2015-02-11 |
2016-08-18 |
Merck Sharp & Dohme Corp. |
Substituted pyrazole compounds as rorgammat inhibitors and uses thereof
|
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
CA2976790C
(en)
|
2015-02-20 |
2024-02-27 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
US10478494B2
(en)
|
2015-04-03 |
2019-11-19 |
Astex Therapeutics Ltd |
FGFR/PD-1 combination therapy for the treatment of cancer
|
|
WO2016179343A1
(en)
|
2015-05-05 |
2016-11-10 |
Lycera Corporation |
DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
|
|
CN107980042B
(zh)
|
2015-06-11 |
2021-10-08 |
莱斯拉公司 |
用作RORγ激动剂和用于治疗疾病的芳基二氢-2H-苯并[b][1,4]噁嗪磺酰胺和相关化合物
|
|
WO2017050865A1
(en)
|
2015-09-23 |
2017-03-30 |
Janssen Pharmaceutica Nv |
Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
|
|
HUE050567T2
(hu)
|
2015-09-23 |
2020-12-28 |
Janssen Pharmaceutica Nv |
Triciklusos heterociklusok rák kezelésére
|
|
JP2018531958A
(ja)
|
2015-10-27 |
2018-11-01 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
ＲＯＲγＴ阻害薬としてのヘテロアリール置換安息香酸及びその使用
|
|
US10287272B2
(en)
|
2015-10-27 |
2019-05-14 |
Merck Sharp & Dohme Corp. |
Substituted indazole compounds as RORgammaT inhibitors and uses thereof
|
|
EP3368516B1
(en)
|
2015-10-27 |
2020-07-15 |
Merck Sharp & Dohme Corp. |
SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
|
|
US9630968B1
(en)
|
2015-12-23 |
2017-04-25 |
Arqule, Inc. |
Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
|
|
US10709708B2
(en)
|
2016-03-17 |
2020-07-14 |
The University Of North Carolina At Chapel Hill |
Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
|
|
GB201604647D0
(en)
|
2016-03-18 |
2016-05-04 |
Mission Therapeutics Ltd |
Novel compounds
|
|
AR108325A1
(es)
|
2016-04-27 |
2018-08-08 |
Samumed Llc |
Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
|
|
AR108326A1
(es)
|
2016-04-27 |
2018-08-08 |
Samumed Llc |
Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
|
|
WO2017205536A2
(en)
*
|
2016-05-24 |
2017-11-30 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
US10933068B2
(en)
*
|
2016-05-26 |
2021-03-02 |
Sonic Master Limited |
Modulators of DUX4 for regulation of muscle function
|
|
ES2926149T3
(es)
*
|
2016-06-02 |
2022-10-24 |
Celgene Corp |
Agentes antipalúdicos animales y humanos
|
|
WO2018029336A1
(en)
|
2016-08-12 |
2018-02-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway.
|
|
AU2017315343A1
(en)
|
2016-08-24 |
2019-02-28 |
Arqule, Inc. |
Amino-pyrrolopyrimidinone compounds and methods of use thereof
|
|
US10253036B2
(en)
|
2016-09-08 |
2019-04-09 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
|
EP3509421A4
(en)
|
2016-09-08 |
2020-05-20 |
Kala Pharmaceuticals, Inc. |
CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
|
|
WO2018048750A1
(en)
|
2016-09-08 |
2018-03-15 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
|
JP2020512975A
(ja)
|
2017-03-28 |
2020-04-30 |
ピメラ，インク． |
Ｐｏｌ１阻害剤の新規な結晶形態
|
|
MX2019010302A
(es)
|
2017-03-30 |
2019-11-21 |
Hoffmann La Roche |
Isoquinolinas como inhibidores de hpk1.
|
|
CN110809471A
(zh)
|
2017-04-28 |
2020-02-18 |
阿沙纳生物科学公司 |
治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
GB201709840D0
(en)
|
2017-06-20 |
2017-08-02 |
Inst Of Cancer Research: Royal Cancer Hospital |
Methods and medical uses
|
|
US10604514B2
(en)
*
|
2017-10-19 |
2020-03-31 |
Samumed, Llc |
6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof
|
|
US10413537B2
(en)
|
2017-10-27 |
2019-09-17 |
Samumed, Llc |
6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof
|
|
US10653688B2
(en)
|
2017-10-27 |
2020-05-19 |
Samumed, Llc |
6-(6-membered heteroaryl and aryl)isoquinolin-3-yl carboxamides and preparation and use thereof
|
|
US10703748B2
(en)
|
2017-10-31 |
2020-07-07 |
Samumed, Llc |
Diazanaphthalen-3-yl carboxamides and preparation and use thereof
|
|
KR102956194B1
(ko)
|
2018-05-04 |
2026-04-23 |
인사이트 코포레이션 |
Fgfr 억제제의 염
|
|
RS66310B1
(sr)
|
2018-05-04 |
2025-01-31 |
Incyte Corp |
Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
|
|
JP7386841B2
(ja)
*
|
2018-07-24 |
2023-11-27 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
イソキノリン化合物及びその使用
|
|
TW202024053A
(zh)
*
|
2018-10-02 |
2020-07-01 |
美商建南德克公司 |
異喹啉化合物及其用途
|
|
TW202023558A
(zh)
|
2018-10-03 |
2020-07-01 |
美商建南德克公司 |
8-胺基異喹啉化合物及其用途
|
|
MA53921A
(fr)
|
2018-10-17 |
2022-01-26 |
Array Biopharma Inc |
Inhibiteurs de protéine tyrosine phosphatase
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021004547A1
(en)
*
|
2019-07-11 |
2021-01-14 |
Guangdong Newopp Biopharmaceuticals Co., Ltd. |
Heterocyclic compounds as inhibitors of hpk1
|
|
US12122767B2
(en)
|
2019-10-01 |
2024-10-22 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
GEP20247679B
(en)
|
2019-10-14 |
2024-10-10 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
MX2022006691A
(es)
|
2019-12-04 |
2022-09-19 |
Incyte Corp |
Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
|
|
WO2021113479A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
EP4090663A1
(en)
|
2020-01-15 |
2022-11-23 |
Blueprint Medicines Corporation |
Map4k1 inhibitors
|
|
WO2021257857A1
(en)
|
2020-06-19 |
2021-12-23 |
Incyte Corporation |
Naphthyridinone compounds as jak2 v617f inhibitors
|
|
WO2021257863A1
(en)
|
2020-06-19 |
2021-12-23 |
Incyte Corporation |
Pyrrolotriazine compounds as jak2 v617f inhibitors
|
|
US11767323B2
(en)
|
2020-07-02 |
2023-09-26 |
Incyte Corporation |
Tricyclic pyridone compounds as JAK2 V617F inhibitors
|
|
IL299612A
(en)
|
2020-07-02 |
2023-03-01 |
Incyte Corp |
Tricyclic urea compounds as JAK2 V617F inhibitors
|
|
US11661422B2
(en)
|
2020-08-27 |
2023-05-30 |
Incyte Corporation |
Tricyclic urea compounds as JAK2 V617F inhibitors
|
|
CA3196620A1
(en)
|
2020-10-05 |
2022-04-14 |
Enliven Therapeutics, Inc. |
5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases
|
|
CN114380752A
(zh)
*
|
2020-10-22 |
2022-04-22 |
南开大学 |
一种制备n-取代-2，4-喹唑啉二酮类化合物的合成方法
|
|
US11919908B2
(en)
|
2020-12-21 |
2024-03-05 |
Incyte Corporation |
Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
|
|
CA3211748A1
(en)
|
2021-02-25 |
2022-09-01 |
Incyte Corporation |
Spirocyclic lactams as jak2 v617f inhibitors
|
|
EP4323405A1
(en)
|
2021-04-12 |
2024-02-21 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
TW202313610A
(zh)
|
2021-06-09 |
2023-04-01 |
美商英塞特公司 |
作為ｆｇｆｒ抑制劑之三環雜環
|
|
CA3220274A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
CN115583946B
(zh)
*
|
2021-07-06 |
2026-01-16 |
赛诺哈勃药业（成都）有限公司 |
杂环化合物及其作为cdk抑制剂的用途
|
|
MX2024000751A
(es)
|
2021-07-14 |
2024-03-25 |
Blueprint Medicines Corp |
Compuestos heterociclicos como inhibidores de map4k1.
|
|
SMT202500447T1
(it)
|
2021-11-02 |
2026-01-12 |
Flare Therapeutics Inc |
Agonisti inversi di pparg e loro usi
|
|
WO2023126951A1
(en)
|
2022-01-03 |
2023-07-06 |
Yeda Research And Development Co. Ltd. |
Inhibitors of autophagy-related protein-protein interactions
|
|
IL315647A
(en)
|
2022-03-17 |
2024-11-01 |
Incyte Corp |
Tricyclic urea compounds as Jak2 and 617f inhibitors
|
|
CN116731030B
(zh)
*
|
2023-06-07 |
2026-03-31 |
湖北医药学院 |
几种呋喃并嘧啶-布洛芬杂合衍生物的合成方法及抗肿瘤的应用
|
|
WO2025010279A2
(en)
*
|
2023-07-03 |
2025-01-09 |
Resero Therapeutics, Llc. |
Polo-like kinase 1 inhibitors
|
|
WO2026148270A1
(en)
*
|
2025-01-03 |
2026-07-09 |
Resero Therapeutics, Llc |
Polo-like kinase 1 inhibitors
|